EA199900953A1 - ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p38 КИНАЗЫ - Google Patents

ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p38 КИНАЗЫ

Info

Publication number
EA199900953A1
EA199900953A1 EA199900953A EA199900953A EA199900953A1 EA 199900953 A1 EA199900953 A1 EA 199900953A1 EA 199900953 A EA199900953 A EA 199900953A EA 199900953 A EA199900953 A EA 199900953A EA 199900953 A1 EA199900953 A1 EA 199900953A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
inhibitors
substituted pyrazoles
class
correspond
Prior art date
Application number
EA199900953A
Other languages
English (en)
Other versions
EA003925B1 (ru
Inventor
Ашок Анантанараян
Майкл Клэр
Пол В. Коллинз
Джойс Зову Крич
Раджеш Деврадж
Даньел Л. Флинн
Лифенг Дженг
Гуннар Дж. Хэнсон
Фрэнсис Дж. Козик
Шуюань Ляо
Ричард А. Партис
Шашидхар Н. Рао
Шон Радж Селнесс
Майкл С. Саут
Майкл А. Стили
Ричард М. Уэйер
Ксянгдонг Ксу
Original Assignee
Дж.Д.Сирл Энд Ко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дж.Д.Сирл Энд Ко filed Critical Дж.Д.Сирл Энд Ко
Publication of EA199900953A1 publication Critical patent/EA199900953A1/ru
Publication of EA003925B1 publication Critical patent/EA003925B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описан класс производных пиразола для использования при лечении расстройств, опосредованных p38 киназой. Соединения, представляющие особый интерес, определены формулой (I)где R, R, Rи Rсоответствуют приведенному описанию.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900953A 1997-05-22 1998-05-22 ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ EA003925B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
EA199900953A1 true EA199900953A1 (ru) 2000-10-30
EA003925B1 EA003925B1 (ru) 2003-10-30

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900953A EA003925B1 (ru) 1997-05-22 1998-05-22 ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ

Country Status (24)

Country Link
EP (1) EP1000055A1 (ru)
JP (1) JP2002508754A (ru)
KR (1) KR20010012854A (ru)
CN (1) CN1264377A (ru)
AP (1) AP1246A (ru)
AU (1) AU754830C (ru)
BG (1) BG64313B1 (ru)
BR (1) BR9809147A (ru)
CA (1) CA2291115A1 (ru)
EA (1) EA003925B1 (ru)
EE (1) EE9900527A (ru)
GE (1) GEP20033053B (ru)
HU (1) HUP0001880A3 (ru)
ID (1) ID22982A (ru)
IL (1) IL132991A (ru)
IS (1) IS5257A (ru)
NO (1) NO995695L (ru)
NZ (1) NZ501112A (ru)
OA (1) OA12981A (ru)
PL (1) PL337020A1 (ru)
SK (1) SK157899A3 (ru)
TR (1) TR200000235T2 (ru)
WO (1) WO1998052940A1 (ru)
ZA (1) ZA984358B (ru)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (ru) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000019824A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
DE69903976T2 (de) 1998-12-16 2003-07-24 Aventis Pharma Ltd Heteroaryl-zyklische acetale
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
US6511997B1 (en) 1998-12-25 2003-01-28 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
KR20020015308A (ko) 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
ES2239596T3 (es) * 1999-06-03 2005-10-01 Teikoku Hormone Mfg. Co., Ltd. Compuestos de pirazol sustituidos.
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
SK3572002A3 (en) * 1999-08-13 2002-07-02 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU7922100A (en) * 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
AU2001284823B2 (en) 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
WO2002062792A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
PT1397364E (pt) 2001-05-24 2007-10-22 Lilly Co Eli Novos derivados de pirrole como agentes farmacêuticos
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
CN1321644C (zh) 2001-09-25 2007-06-20 法玛西雅公司 制备取代的吡唑的方法
TW200400960A (en) * 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
TW200505447A (en) 2003-02-07 2005-02-16 Daiichi Seiyaku Co Pyrazole derivative
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AP2326A (en) 2004-08-12 2011-11-24 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ATE538118T1 (de) 2004-12-28 2012-01-15 Aska Pharm Co Ltd Pyrimidinylisoxazolderivat
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2008001930A1 (fr) 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Dérivé de pyridylisoxazole
CA2655999A1 (en) * 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
CN101610754A (zh) 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
JP2010533147A (ja) * 2007-07-13 2010-10-21 アデックス ファルマ エス．エイ． 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
CL2008003407A1 (es) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CL2009000904A1 (es) 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CA2724214A1 (en) 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
MX2011000738A (es) 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
CA2735204C (en) * 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
CN102177138A (zh) * 2008-10-23 2011-09-07 隆萨有限公司 合成取代的吡唑类的方法
RU2528406C2 (ru) * 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
EP2438049B1 (en) 2009-06-02 2014-05-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP2013503129A (ja) * 2009-08-26 2013-01-31 ノバルティス アーゲー テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
EP2528909B1 (en) 2010-01-27 2016-06-22 Nerviano Medical Sciences S.r.l. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
CN103153980B (zh) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
JP5684923B2 (ja) * 2010-12-20 2015-03-18 ファイザー・インク カゼインキナーゼ阻害剤としての新規縮合ピリジン化合物
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
EP2744783A1 (en) 2011-08-17 2014-06-25 Boehringer Ingelheim International GmbH Indenopyridine derivatives
MX351460B (es) 2011-10-06 2017-10-16 Bayer Ip Gmbh Heterociclilpiri(mi)dinilpirazol.
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
DE102011115525A1 (de) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Zweiteilige Flasche mit einem darin angeordneten Trockenmittel
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
ES2900815T3 (es) * 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
CN105814024B (zh) * 2013-12-12 2018-04-17 住友化学株式会社 芳族化合物及其用途
CN104829536B (zh) * 2015-05-04 2017-12-29 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
ES2791340T3 (es) * 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
IS5257A (is) 1999-11-19
EE9900527A (et) 2000-06-15
BR9809147A (pt) 2000-08-01
EP1000055A1 (en) 2000-05-17
CA2291115A1 (en) 1998-11-26
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
AU754830C (en) 2004-02-12
OA12981A (en) 2006-10-13
HUP0001880A3 (en) 2002-03-28
BG64313B1 (bg) 2004-09-30
IL132991A0 (en) 2001-03-19
CN1264377A (zh) 2000-08-23
IL132991A (en) 2005-11-20
HUP0001880A2 (en) 2001-03-28
AP9901715A0 (en) 1999-12-31
NZ501112A (en) 2002-10-25
AU7588398A (en) 1998-12-11
SK157899A3 (en) 2000-08-14
TR200000235T2 (tr) 2000-05-22
BG103964A (en) 2000-08-31
NO995695L (no) 2000-01-21
NO995695D0 (no) 1999-11-19
AU754830B2 (en) 2002-11-28
JP2002508754A (ja) 2002-03-19
GEP20033053B (en) 2003-08-25
ZA984358B (en) 1999-05-24
ID22982A (id) 1999-12-23
AP1246A (en) 2004-02-07
KR20010012854A (ko) 2001-02-26
EA003925B1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
EA199900953A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p38 КИНАЗЫ
EA200100554A1 (ru) Замещенные пиразолы как ингибиторы p38 киназы
EA199900853A1 (ru) Замещенные производные бензопирана для лечения воспалительных процессов
BR9809451A (pt) Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
EA199800633A1 (ru) Новые замещенные производные имидазола
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
NO952397L (no) Substituerte pyrazoler som CRF antagonister
TR200103787T1 (tr) Hücre-dışı sinyal ayarlı kinazların(ERK) inhibitörü olarak yararlı pirazol bileşimler
BR9810342A (pt) Novos compostos imidazola substituìdos
HK1023987A1 (en) Sulphinic acid derivatives, method for producing, and their use
BG92804A (bg) 4-бензоилизоксазолови производни
NO970162L (no) Substituerte pyrimidinforbindelser og anvendelse derav
PT691128E (pt) Metodos de administracao de antagonistas de crf
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
EA199800675A1 (ru) Дифенилстильбены как пролекарства к ингибиторам циклооксигеназы(сох-2)
MXPA05006957A (es) Nuevos derivados de fosforamida.
EA199801084A1 (ru) Спосб получения фенилгетероциклических соединений, используемых в качестве ингибиторов циклооксигеназы-2
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
ITMI20022739A1 (it) Derivati ftalazinici inibitori della fosfodiesterasi 4.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU